"**Trauma Care in the UK** Trauma remains the fourth leading cause of death in western countries and the leading cause of death for people under 40\. 50,000 people are seriously injured each year in the UK, causing significant economic, social and environmental impact on government and society, estimated to cost the nation in excess of £3.75bn. The Advanced Trauma Life Support protocol (ATLS) has standardised the approach to trauma and is used globally, however unacceptable levels of variation still exist. It is estimated 450 to 600 lives would be saved per year in England alone with better adherence to ATLS, saving an estimated £450m in direct and indirect costs. **Prototype Application** We have developed a prototype application that maps a subset of the trauma protocol in collaboration with trauma specialists, the DHI and Scottish Trauma Network. Our aim was to explore the impact of a digital solution on care delivery and outcomes. Simulations of the prototype in the Edinburgh Royal Infirmary and Glasgow Queen Elizabeth hospitals showed that the app focused teams around the protocol, helping them deliver care more consistently. The prototype received unanimous support and the Scottish Trauma Network subsequently backed the project with £70,000 to expand the prototype to explore all aspects of the ATLS protocol. **Next Steps with Innovate Funding** We see a significant opportunity to expand the application with decision support algorithms that actively help the team adhere to ATLS in live clinical cases. The result would be a radical improvement in ATLS delivery. Reduced variation would improve outcomes, reduce the cost burden of rehab on the NHS and ultimately save lives. To use this tool in a clinical setting, it will need to be certified as a medical device. Innovating within the healthcare space with decision support is challenging. Tools of this nature are relatively new, clinical certification is expensive and crucial to demonstrate patient safety and enable future commercialisation. Information governance issues are often a barrier to adoption. However, we believe we are well placed to tackle these issues with a strong consortium of companies, clinicians, and commercial partners. Innovate UK funding will be critical, without which, we will not be able to attempt the project and realise this exciting opportunity."